University of Michigan researchers reported that a yeast-derived, universal influenza vaccine candidate protected mice against multiple influenza A strains by targeting a conserved viral protein. The approach uses genetically engineered baker’s yeast to manufacture virus-like particles (VLPs) displaying the influenza antigen. The preclinical findings suggest the platform could support broader, potentially longer-lasting protection compared with conventional seasonal vaccines, which typically must be reformulated. The work positions the system as an alternative manufacturing and antigen-display strategy using a scalable biological production route. While mouse protection does not translate directly to human efficacy, the study adds to a growing body of universal-flu research aimed at reducing antigenic escape risk for recurring influenza seasons.